IMMS focusses on the integration of various sensor principles of different biological and chemical measurands into one integrated electronic device for extensive and precise diagnostics. The work is based on cost-efficient standard semiconductor manufacturing processes (CMOS) which IMMS also uses for these new diagnostic approaches.
IMMS adapts its systems to application-specific needs by means of particular functionalisation of surfaces and the use of biocompatible material. These solutions should pave the way for fast, reliable, cost-efficient and automated in-vitro diagnostics, such as early recognition of cancer.
In the INSPECT research project IMMS is developing systems for the early recognition of breast, cervical, prostate and lung cancers using semiconductor chips as well as immunological and cell-based biotechnological methods. IMMS is working on an interdisciplinary interface between biology and microelectronics for signal processing. In addition, further concepts for microelectronic-based point-of-care diagnostics and for personalized cancer immunotherapies are being investigated. IMMS is currently testing the first prototypes of the miniaturized diagnostic devices. The research partners iba Institut für Bioprozess- und Analysenmesstechnik e.V. Heiligenstadt, Senova Gesellschaft für Biowissenschaft und Technik mbH Weimar, CDA GmbH Suhl and X-FAB Semiconductor Foundries AG Erfurt are contributing to the novel solutions. IMMS is coordinating the consortium.
The INSPECT project receives funding from the “Land” of Thüringen and the European Union (European Regional Development Fund (ERDF, German EFRE) under the reference 2015 FE 9159.